Amgen (STU:AMG) Unearned Premiums

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AMG Amgen Inc STU:AMG
86 GF Score
Price €342.80
GF Value €317.51
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Amgen Unearned Premiums?

Unearned Premiums only applies to insurance companies.

STU:AMG
86GF Score
Amgen Inc STU:AMG
Unearned Premiums is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Amgen (STU:AMG) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of €342.80 is trading 8% above its estimated GF Value™ of €317.51. GuruFocus considers Amgen to be Fairly Valued.

Key valuation signals for STU:AMG:

  • Unearned Premiums:
  • GF Value™: €317.51 vs. price of €342.80 (8% above fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the STU:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is one of the world's largest biotechnology companies, discovering, developing, and manufacturing biologic and small-molecule therapies. Its portfolio spans general medicine, including cholesterol-lowering Repatha and osteoporosis treatments Prolia and EVENITY; inflammation, with Otezla, Enbrel, and biosimilars; oncology, including BiTE therapy Blincyto, KRAS inhibitor Lumakras, and Vectibix; and rare diseases, substantially expanded by the 2023 acquisition of Horizon Therapeutics, which added thyroid eye disease treatment Tepezza, gout therapy Krystexxa, and Uplizna. Amgen is developing MariTide, an obesity therapy, in one of its highest-profile pipeline programs, and operates a leading biosimilars business. Founded in 1980, a pioneer of the biotechnology industry, Amgen is headquartered in Thousand Oaks, California, and markets in approximately 100 countries.
86GF Score

Get the complete analysis for STU:AMG

Unearned Premiums is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€342.80
Price
€317.51
GF Value